Document is current

Article History

Accepted: 10 June 2025

First Online: 1 July 2025

Change Date: 10 August 2025

Change Type: Update

Change Details: Article note related to podcast and transcript updated

Declarations

:

: This podcast was sponsored by EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA.

: The authors received no honoraria related to the development of this publication. Petros Grivas is an Editorial Board member of Targeted Oncology. Petros Grivas was not involved in the selection of peer reviewers for the article nor any of the subsequent editorial decisions. Petros Grivas in the last 2 years reports consulting with AbbVie, Asieris Pharmaceuticals, Astellas Pharma, AstraZeneca, Bicycle Therapeutics, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Fresenius Kabi, Gilead Sciences, ImmunityBio, Janssen, MSD, Pfizer, Replimune, Roche, and Strata Oncology and institutional research funding from Acrivon Therapeutics, ALX Oncology, Bristol Myers Squibb, EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, Gilead Sciences, Genentech, MSD, and QED Therapeutics. Helen H. Moon has received honoraria from Merck and Pfizer and institutional research funding from Amgen, Apollomics, Arcus Biosciences, AVEO, Bristol Myers Squibb, Genentech, HUYA Bioscience International, Nektar, Prometheus, RevImmune, and Seagen.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Petros Grivas and Helen H. Moon contributed equally to all aspects of the development of this podcast, including concept and design, drafting of the outline, and interpretation of the data discussed. Both authors read and approved the final transcript.